Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

PTC Therapeutics Inc. : PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2013 | 11:03am CET

SOUTH PLAINFIELD, NJ - June 20, 2013 - PTC Therapeutics, Inc. (PTC) today announced the pricing of its initial public offering of 8,372,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the shares in the offering are being sold by PTC. In addition, the underwriters have an option for a period of 30 days to purchase up to 1,255,800 additional shares of common stock from PTC at the public offering price, less the underwriting discount. PTC's common stock has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "PTCT" on June 20, 2013.

J.P. Morgan and Credit Suisse are acting as joint book-running managers for the offering. Cowen and Company is acting as co-lead manager and Wedbush PacGrow Life Sciences as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 19, 2013.

The offering is being made only by means of a prospectus, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204; or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010; telephone: 800-221-1037; email: newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

ABOUT PTC THERAPEUTICS, INC.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders and infectious diseases.

CONTACT

Jane Baj

PTC Therapeutics, Inc.

908-912-9167

jbaj@ptcbio.com

Sheryl Seapy

Pure Communications

sheryl@purecommunicationsinc.com


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
10:07p NUTRISYSTEM : Announces Fourth Quarter and Full Year 2016 Financial Results
10:07p ICF : Reports Fourth Quarter and Full Year 2016 Results
10:07p MEETME SETS FOURTH QUARTER AND FISCAL YEAR 2016 CONFERENCE CALL FOR MARCH 6 AT 4 : 30 p.m. Eastern Time
10:07p BLACK KNIGHT FINANCIAL SERVICES : Completes Repricing of Its $394 Million Senior Secured Term Loan B Facility
10:07p EVERBRIDGE : Announces Intention to File Registration Statement for Public Offering of Common Stock
10:06p ONCOCYTE : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
10:06p GREEN BRICK PARTNERS : Announces Dates for 10-K Filing and Earnings Call
10:06p DYNAGAS LNG PARTNERS LP : Reports Results for the Three Months and Year Ended December 31, 2016
10:06p The Habit Restaurants to Present at the Raymond James & Associates’ 38th Annual Institutional Investors Conference
10:06p ARDELYX : Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
Latest news
Advertisement
Hot News 
2.31%ESURE : UK insurer esure Group sees 2016 profit ahead of expectations
-7.16%DIRECT LINE INSURANCE : expects lower profit before tax due to discount rate change
-9.64%TRINITY MIRROR : to accelerate digital strategy after print decline
3.41%BUNZL : British distributor Bunzl eyes Trump boost in 2017
-2.46%FTSE ends higher on some positive earnings, insurers slip
Most Read News
01:12p Wall Street treads water ahead of Trump's Tuesday speech
11:50a LSE scuppers Deutsche Boerse merger hopes by rejecting EU demand
12:32p Buffett's Berkshire more than doubled its stake in Apple - CNBC
04:38a BANK VTB : Russia's VTB plans to slim down in Europe, keep London as hub
08:20a ING GROEP : Euro zone banks cut cross-border lending as stability fears grow
Most recommended articles
04:58a Amazon, Netflix grab a share of Oscar glory
02/23DJVIVENDI : Full-Year Earnings Beat Estimates
04:01pDJU.S. Grains, Soybeans Drift to Multiweek Lows
04:01pDJTwo Retailers, One Big Worry -- Ahead of the Tape
03:38pDJJOHNSON & JOHNSON : Prescription Unit List Prices Rose 8.5% Last Year